When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out--results from critical drug trials weren't likely to be reported for two years. The reason to hold onto shares of Incyte (INCY), however, is how close […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
